Education
About Us
Working with TipRanks
Follow Us
OS Therapies Incorporated (OSTX)
:OSTX
RESEARCH TOOLSreports
OSTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.33 - $7.00
Previous CloseN/A
Volume28.07K
Average Volume (3M)200.18K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$80.79K
Total Debt (Recent Filing)$7.07M
Price to Earnings (P/E)―
Beta-1.28
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding21,663,810
10 Day Avg. Volume87,294
30 Day Avg. Volume200,183
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.00Price Target Upside1027.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessOST-HER2 achieved successful results in a Phase 2b study for recurrent osteosarcoma, meeting the primary endpoint of 12-month event-free survival.
Financial OutlookDue to the positive outcomes and potential for accelerated approval, the revenue risk adjustment was lowered, increasing the 12-month price target to $15.
Regulatory ProgressThe positive trial data positions OS Therapies to engage with the FDA for potential accelerated approval of OST-HER2.
Bears Say
Cash ReservesOS Therapies has $1.8 million in cash and a $15 million equity line, which may only provide financial runway into the first half of 2026 without additional monetization of non-core programs.
---
Options Prices
Currently, No data available
---
Ownership Overview
28.55% Insiders
0.51% Other Institutional Investors
70.93% Public Companies and
Individual Investors
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.33 and its highest was $7.00 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
Currently, no data Available
When is OS Therapies Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on Nov 15, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.06.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 21,663,810 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -13.636%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
---
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
---
OSTX Stock 12 Month Forecast
Average Price Target
$15.00
▲(1027.82% Upside)
Technical Analysis
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Hepion Pharmaceuticals
―
Virpax Pharmaceuticals
―
ZyVersa Therapeutics
―
Best Analysts Covering OSTX
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-43.90%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -43.90% per trade.
---